DYADIC INTERNATIONAL INC Other General and Administrative Expense
DYADIC INTERNATIONAL INC (DYAI) reported Other General and Administrative Expense of $285.49 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherGeneralAndAdministrativeExpense · last filed 2026-08-12
- DYADIC INTERNATIONAL INC other general and administrative expense for the quarter ending 2026-06-30 was $285.49K, a 13.58% increase year-over-year.
- DYADIC INTERNATIONAL INC other general and administrative expense for the quarter ending 2026-03-31 was $240.01K, a 1.43% decline year-over-year.
- DYADIC INTERNATIONAL INC other general and administrative expense for the quarter ending 2025-12-31 was $194.97K, a 10.08% decline year-over-year.
- DYADIC INTERNATIONAL INC other general and administrative expense for the quarter ending 2025-09-30 was $200.16K, a 8.62% decline year-over-year.
- DYADIC INTERNATIONAL INC other general and administrative expense for fiscal 2025 was $889.99K, a 10.60% decline from fiscal 2024.
- DYADIC INTERNATIONAL INC other general and administrative expense for fiscal 2024 was $995.50K.
| Period end | Other General and Administrative Expense 3 month | Other General and Administrative Expense 6 month | Other General and Administrative Expense 9 month | Other General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $285.49K 10-Q · filed 2026-08-12 | $525.50K 10-Q · filed 2026-08-12 | $720.48K derived: sum of 3 quarters · filed 2026-08-12 | $920.64K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $240.01K 10-Q · filed 2026-05-13 | $434.98K derived: sum of 2 quarters · filed 2026-05-13 | $635.15K derived: sum of 3 quarters · filed 2026-05-13 | $886.50K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $194.97K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $395.14K derived: sum of 2 quarters · filed 2026-03-25 | $646.49K derived: sum of 3 quarters · filed 2026-08-12 | $889.99K 10-K · filed 2026-03-25 |
| 2025-09-30 | $200.16K 10-Q · filed 2025-11-12 | $451.52K derived: sum of 2 quarters · filed 2026-08-12 | $695.01K 10-Q · filed 2025-11-12 | $911.84K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $251.35K 10-Q · filed 2026-08-12 | $494.85K 10-Q · filed 2026-08-12 | $711.67K derived: sum of 3 quarters · filed 2026-08-12 | $930.73K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $243.50K 10-Q · filed 2026-05-13 | $460.32K derived: sum of 2 quarters · filed 2026-05-13 | $679.37K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | $216.82K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $435.88K derived: sum of 2 quarters · filed 2026-03-25 | $995.50K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $219.05K 10-Q · filed 2025-11-12 | $778.68K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |